Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331

Author:

Maloney Kelly W.12,Devidas Meenakshi3,Wang Cindy4,Mattano Leonard A.5,Friedmann Alison M.6,Buckley Patrick7,Borowitz Michael J.8,Carroll Andrew J.9,Gastier-Foster Julie M.1011,Heerema Nyla A.12,Kadan-Lottick Nina13,Loh Mignon L.1415,Matloub Yousif H.16,Marshall David T.17,Stork Linda C.18,Raetz Elizabeth A.1920,Wood Brent2122,Hunger Stephen P.2324,Carroll William L.1920,Winick Naomi J.2526

Affiliation:

1. Department of Pediatrics, University of Colorado, Aurora, CO

2. Children’s Hospital Colorado, Aurora, CO

3. Department of Global Pediatric Medicine, St Jude Children’s Research Hospital, Memphis, TN

4. Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, FL

5. HARP Pharma Consulting, Mystic, CT

6. Department of Pediatrics, Massachusetts General Hospital Cancer Center, Boston, MA

7. Department of Pathology, Duke University Medical Center, Durham, NC

8. Department of Pathology, Johns Hopkins University, Baltimore, MD

9. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL

10. Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH

11. Department of Pediatrics, Ohio State University College of Medicine, Columbus, OH

12. Department of Pathology, Wexner Medical Center, Ohio State University, Columbus, OH

13. Department of Pediatrics, Yale University, New Haven, CT

14. Department of Pediatrics, Benioff Children’s Hospital, San Francisco, CA

15. Helen Diller Family Comprehensive Cancer, University of California, San Francisco, CA

16. Department of Pediatrics, Rainbow Babies and Children’s Hospital, Cleveland, OH

17. Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC

18. Department of Pediatrics, Oregon Health & Science University, Portland, OR

19. Perlmutter Cancer Center, New York University (NYU) Langone Medical Center, New York, NY

20. Department of Pediatrics, NYU Langone Medical Center, New York, NY

21. Department of Pathology, University of Washington, Seattle, WA

22. Department of Medicine, University of Washington, Seattle, WA

23. Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA

24. Perelman School of Medicine at University of Philadelphia, Philadelphia, PA

25. Department of Pediatrics, University of Texas (UT) Southwestern, Dallas, TX

26. Simmons Cancer Center, UT Southwestern, Dallas, TX

Abstract

PURPOSE Children’s Oncology Group (COG) AALL0331 tested whether intensified postinduction therapy that improves survival in children with high-risk B-cell acute lymphoblastic leukemia (ALL) would also improve outcomes for those with standard-risk (SR) ALL. PATIENTS AND METHODS AALL0331 enrolled 5,377 patients between 2005 and 2010. All patients received a 3-drug induction with dexamethasone, vincristine, and pegaspargase (PEG) and were then classified as SR low, SR average, or SR high. Patients with SR-average disease were randomly assigned to receive either standard 4-week consolidation (SC) or 8-week intensified augmented Berlin-Frankfurt-Münster (BFM) consolidation (IC). Those with SR-high disease were nonrandomly assigned to the full COG-augmented BFM regimen, including 2 interim maintenance and delayed intensification phases. RESULTS The 6-year event-free survival (EFS) rate for all patients enrolled in AALL0331 was 88.96% ± 0.46%, and overall survival (OS) was 95.54% ± 0.31%. For patients with SR-average disease, the 6-year continuous complete remission (CCR) and OS rates for SC versus IC were 87.8% ± 1.3% versus 89.1% ± 1.2% ( P = .52) and 95.8% ± 0.8% versus 95.2% ± 0.8% ( P = 1.0), respectively. Those with SR-average disease with end-induction minimal residual disease (MRD) of 0.01% to < 0.1% had an inferior outcome compared with those with lower MRD and no improvement with IC (6-year CCR: SC, 77.5% ± 4.8%; IC, 77.1% ± 4.8%; P = .71). At 6 years, the CCR and OS rates among 635 nonrandomly treated patients with SR-high disease were 85.55% ± 1.49% and 92.97% ± 1.08%, respectively. CONCLUSION The 6-year OS rate for > 5,000 children with SR ALL enrolled in AALL0331 exceeded 95%. The addition of IC to treatment for patients with SR-average disease did not improve CCR or OS, even in patients with higher MRD, in whom it might have been predicted to provide more value. The EFS and OS rates are excellent for this group of patients with SR ALL, with particularly good outcomes for those with SR-high disease.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3